"Ventilator-Associated Pneumonia as a Major Fatality Disease in Hospitals" is a worthy example of a paper on the respiratory system. Ventilator-associated pneumonia (VAP) is a major fatality disease in hospitals. The disease has very high morbidity, cost of treatment, and mortality. Looking at evidence-based literature on the disease focuses on the clinical interventions used to manage the fatal condition. Implementing preventive measures remains paramount in caring for the ventilated patients. This is evidence that measures are in place in securing improved outcomes in the intensive care unit. Curbing the disease comes with securing a multidisciplinary approach, continued research, and medical protocols during measure implementations.
Most intensive care unit (ICU) patients suffer from ventilator-associated pneumonia (VAP). In contrast to other killer diseases, the mortality rate of VAP-related complications ranges from 20% to 50%. The infections that come with the prolonged duration come with a heightened financial burden. Ventilator-associated pneumonia causes vary and differ depending on patient populations. This calls for different treatment platforms and research to aid in having a clear knowledge of the microbiology component of VAP. Ventilator-associated pneumonia preventions come with a process that secludes important aspects while using different approaches.
Once doctors make the diagnosis, an early dose of antibiotics is administered to the patient to decrease mortality and morbidity. Doctors then manage the situation by putting the patients under therapy to reduce the development of resistant pathogens. The doctors base the therapy depending on the patients’ response to clinical medicine. Continued research investigates the cost of the disease and new methods that can be applied in preventing contamination of ventilator-associated pneumonia. Containing the disease and its effects requires proper research and analysis of existing literature.